Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Unusual Whales

Aug 4, 2026 at 06:02 AM

Information from the Phase 2a clinical trial of the drug OD-001 has been approved for oral presentation at the upcoming United European Gastroenterology Week in October.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Odyssey Therapeutics

ODTX.US

Open

--

High

--

Low

--

Prev Close

--

P/E^TTM

--

Market Cap

--

LongbridgeAI